EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Restoring Tamoxifen Sensitivity in Breast Cancer: The Role of lncRNA MALAT1 and NanoCurcumin as Modulators of Drug Resistance

Fatemeh Nasiri Kenari iD, Masoumeh Saberian iD, Matthew Abikenari iD, Safa Najafi iD, Majid Sadeghizadeh iD

BioMed Research International · 2025

DOI: 10.1155/bmri/5824748 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioMed Research International, 2025. Verfasst von Fatemeh Nasiri Kenari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics, Faculty of Biological Science, Tarbiat Modares University, Tehran, Iran, modares.ac.ir. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Tamoxifen, Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tarbiat Modares University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tamoxifen resistance remains a major clinical challenge in estrogen receptor–positive (ER+) breast cancer, contributing to recurrence and poor prognosis. Long noncoding RNAs (lncRNAs), including MALAT1, UCA1, CYTOR, GAS5, and HOTAIR, have emerged as key regulators of endocrine resistance. Curcumin, a polyphenol with anticancer properties, modulates lncRNA expression, and its bioavailable formulation, NanoCurcumin, enhances therapeutic efficacy. This study evaluates the effects of NanoCurcumin in combination with tamoxifen on lncRNA expression and resistance mechanisms in ER+ breast cancer.

Methods

Plasma levels of the selected lncRNAs were assessed via qRT‐PCR in luminal breast cancer patients receiving tamoxifen alone or in combination with NanoCurcumin oral soft gels for 6 months. Bioinformatics analysis of MALAT1 expression was performed using the GEO database. In vitro, MALAT1 expression was evaluated in breast cancer (MCF7) and normal breast (MCF10) cell lines via qRT‐PCR. Tamoxifen‐resistant MCF7 cells were generated through prolonged treatment, and the effects of NanoCurcumin on MALAT1 expression were analyzed over 4 months.

Results

In clinical samples, NanoCurcumin significantly reduced MALAT1 expression ( p = 0.02) and trended toward decreased UCA1, CYTOR, and HOTAIR while increasing GAS5 expression. Bioinformatics analysis confirmed MALAT1 upregulation in tamoxifen‐resistant cell lines. In vitro, MALAT1 was significantly elevated in MCF7 cells compared to MCF10 and increased over time with tamoxifen treatment alone. NanoCurcumin reversed this trend, sustaining low MALAT1 levels and mitigating resistance.

Conclusion

Our findings suggest that NanoCurcumin mitigates tamoxifen resistance by downregulating MALAT1, offering a novel epigenetic strategy to enhance endocrine therapy efficacy. Further studies should explore lncRNA‐targeted interventions to improve treatment outcomes in ER+ breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingTamoxifenBreast NeoplasmsDrug Resistance, NeoplasmCurcuminHumansFemaleMCF-7 CellsGene Expression Regulation, NeoplasticCell Line, TumorMiddle AgedNanoparticles

Stichwörter der Autor:innen

NanoCurcuminbreast cancerlncRNA MALAT1plasma biomarkertamoxifen resistance

Substanzen

RNA, Long NoncodingTamoxifenMALAT1 long non-coding RNA, humanCurcuminnanocurcumin

Autor:innen und Institutionen

  • Department of Molecular Genetics, Faculty of Biological Science, Tarbiat Modares University, Tehran, Iran, modares.ac.ir.
  • Department of Hematology and Oncology, Valiasr Hospital, Tehran, Iran.
  • Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA, stanford.edu.
  • Department of Oncology, Motamed Cancer Institute, Tehran, Iran.

ORCID-Profile: Fatemeh Nasiri Kenari, Masoumeh Saberian, Matthew Abikenari, Safa Najafi, Majid Sadeghizadeh

Förderung

  • Tarbiat Modares University

Zitieren

APA

Nasiri Kenari, F., Saberian, M., Abikenari, M., Najafi, S., & Sadeghizadeh, M. (2025). Restoring Tamoxifen Sensitivity in Breast Cancer: The Role of lncRNA MALAT1 and NanoCurcumin as Modulators of Drug Resistance. BioMed Research International. https://doi.org/10.1155/bmri/5824748

Vancouver

Nasiri Kenari F, Saberian M, Abikenari M, Najafi S, Sadeghizadeh M. Restoring Tamoxifen Sensitivity in Breast Cancer: The Role of lncRNA MALAT1 and NanoCurcumin as Modulators of Drug Resistance. BioMed Research International. 2025. doi:10.1155/bmri/5824748

BibTeX
@article{NasiriKenari2025,
  author = {Nasiri Kenari, Fatemeh and Saberian, Masoumeh and Abikenari, Matthew and Najafi, Safa and Sadeghizadeh, Majid},
  title = {Restoring Tamoxifen Sensitivity in Breast Cancer: The Role of lncRNA MALAT1 and NanoCurcumin as Modulators of Drug Resistance},
  journal = {BioMed Research International},
  year = {2025},
  doi = {10.1155/bmri/5824748}
}
Kostenlos starten →